More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.93B
EPS
-0.78
P/E ratio
--
Price to sales
7.88
Dividend yield
--
Beta
1.693097
Previous close
$27.36
Today's open
$27.52
Day's range
$25.49 - $28.15
52 week range
$10.95 - $34
show more
CEO
Ramy Farid
Employees
850
Headquarters
New York, NY
Exchange
Nasdaq Global Select
Shares outstanding
75077794
Issue type
Common Stock
Healthcare
Healthcare Providers & Services
Schrodinger Eyes Growth From AI Assistant Bunsen and Hosted Software Shift
Schrodinger NASDAQ: SDGR is looking to its artificial intelligence assistant Bunsen and a shift toward hosted software contracts to expand use of its molecular discovery platform, executives said at the UBS Global Healthcare Conference.
MarketBeat • Nov 13, 2026

Schrödinger, Inc. (SDGR) Presents at 2026 UBS Global Healthcare Conference Transcript
Schrödinger, Inc. (SDGR) Presents at 2026 UBS Global Healthcare Conference Transcript
Seeking Alpha • Nov 10, 2026

Schrödinger, Inc. (SDGR) Q3 2026 Earnings Call Transcript
Schrödinger, Inc. (SDGR) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

What Schrodinger (SDGR) Said on Its Q3 Earnings Call
Schrodinger NASDAQ: SDGR raised its full-year 2026 outlook for annual contract value and drug discovery revenue after reporting third-quarter growth in both software demand and revenue from its therapeutics collaborations.
MarketBeat • Nov 5, 2026

Schrödinger Reports Third Quarter 2026 Financial Results
NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended September 30, 2026. “We are very pleased with our third quarter performance, delivering 17% ACV growth, $24 million of drug discovery revenue, and raising our full-year ACV and drug discovery revenue outlook. Our strong performance highlights the power of our industry-leading platform and also our business model in which our software and drug discovery businesses reinforce each ot.
Business Wire • Nov 4, 2026

Schrodinger, Inc. (SDGR) Reports Q3 Loss, Beats Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.45 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Earnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to Decline
Schrodinger (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 28, 2026

Schrödinger to Present at UBS Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference. The live presentation will take place on Tuesday, November 10, 2026 at 9:30 a.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational pl.
Business Wire • Oct 28, 2026

Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on October 21, 2026, the company granted restricted stock units (RSUs) with respect to 5,716 shares of the company's common stock to five newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement.
Business Wire • Oct 26, 2026

Schrödinger to Announce Third Quarter 2026 Financial Results on November 4
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its third quarter 2026 financial results on Wednesday, November 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform.
Business Wire • Oct 21, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Schrodinger Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.